Menu
Model Image 22

COOKIES POLICY

Not an actual patient.

Use of cookies

A cookie is a small text file which is placed onto your computer (or other electronic device) when you access our website. We use cookies to enable the website to remember information that you previously input. This helps us to improve the performance of our website for our users by providing content-specific information by tracking how sections of our website are used. We may also use cookies to obtain information for undertaking research and statistical analysis to help improve our content. Cookies allow us to provide you with a better and more efficient user experience, by understanding your preferences and tailoring your access to such preferences.

We do not sell the information we collect from our use of cookies.

Consent

In most cases we will need your consent in order to use cookies on this website.

There is a notice on our home page which describes how we use cookies on this website and which also provides a link to this Cookies Policy. If you use this website after this notification has been displayed to you, we will assume that you consent to our use of cookies for the purposes described in this Cookie Policy and our Privacy Policy. Please note that your consent can be withdrawn at any time, however if you do not consent to cookies being installed on your browser, Sinclair Pharma may not be able to provide you full access to or all the functionality of our websites.

Third-party cookies

We work with third party suppliers who may also set cookies on our website, for example Facebook, Twitter, YouTube, WordPress, Google Analytics, google.com, Mediaplex, doubleclick.net and scorecardresearch.com. These third party suppliers are responsible for the cookies they set on our website. If you want further information please go to the website of the relevant third party.

How to turn off cookies

You can turn off cookies by changing your browser settings to erase cookies from your computer’s hard drive, block all cookies, or receive a warning before a cookie is stored. Please check your Internet browser’s instructions to learn more about these functions.

Please be aware though that you may lose some of the functionality of this website if you do not allow cookies.

To find out more about cookies and how to manage and/or delete them, please visit aboutcookies.org or allaboutcookies.org for further information.

This policy was updated in August 2018.

INDICATION:

The EU approved intended use is: Ellansé (a Poly-ɛ-caprolactone-based dermal filler) is an injectable implant, indicated for subdermal implantation in the face for the lasting correction of wrinkles and facial aging signs or conditions.

INDICATION:

The EU approved intended use is: Ellansé (a Poly-ɛ-caprolactone-based dermal filler) is an injectable implant, indicated for subdermal implantation in the face for the lasting correction of wrinkles and facial aging signs or conditions.

Important Safety Considerations:

Like all procedures of this type there is a possibility of adverse events, although not everybody experiences them. These adverse events include but are not limited to infection, minimal acute inflammatory tissue reaction (redness, swelling, rash, oedema, erythema, lumps/nodules etc.), pain (which may be temporary or persistent in nature), transient haematoma or bruising.

Other potential adverse events include

- Injection related reactions, include itching, discoloration or tenderness may occur at the site of the injection. These usually resolve spontaneously within several days after the injection.

- As with any implant material possible adverse reactions that may occur include, but are not limited to the following: hypersensitivity, allergic reactions, inflammation, infection, fistula formation, haematoma, seroma, extrusion, induration formation, inadequate healing, skin discoloration, oedema, contusions/bruises, ecchymosis, inadequate or excessive augmentation, loss of correction, interference with local circulation if injected into a blood vessel resulting in vessel laceration, occlusion, embolism, infarction, and abscess at implant site which may result in induration and/or scar formation.

- Rare but serious adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage, leading to stroke, skin necrosis, damage to underlying facial structures, nausea and vomiting, lack of ocular movement, significant skin changes, ptosis, exotropia and neurological complications.

- Adverse events, other than mentioned above, could occur as can be with any medical intervention.

All (potential) adverse side effects and incidents should be reported immediately to the Sinclair Corporate Safety Group: quality@sinclair.com